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Abstract
Background
Alkaline phosphatase (ALP) has been suggested to be associated with cardiovascular dis-
ease (CVD) risk, however, important aspects of the association, such as shape and inde-
pendence from established risk factors, have yet to be characterized in detail. We assessed
the association of ALP with CVD risk and determined its utility for CVD risk prediction.
Methods
Alkaline phosphatase activity was measured at baseline in the PREVEND prospective
cohort involving 6,974 participants aged 28-75 years without pre-existing CVD. Hazard
ratios (95% confidence intervals [CI]) and measures of risk discrimination and reclassifica-
tion were assessed.
Results
During a median follow-up of 10.5 years, 737 participants developed CVD. Serum ALP was
correlated with several risk markers for CVD, with strongest correlations for age (r = 0.30;
P < 0.001), gamma-glutamyltransferase (r = 0.26; P < 0.001), and C-reactive protein (CRP)
(r = 0.25; P < 0.001). There was a non-linear “J-shaped” relationship between ALP and CVD
risk. In analyses adjusted for conventional risk factors, the hazard ratio (95% CI) for CVD in
a comparison of the top quintile versus bottom quintiles 1-4 of ALP values was 1.34 (1.14 to
1.56; P<0.001), which persisted after additional adjustment for potential confounders 1.33
(1.13 to 1.55; P<0.001). However, the association was somewhat attenuated after adjust-
ment for CRP 1.24 (1.05 to 1.45; P=0.009). Addition of information on ALP to a CVD risk
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Conclusions
Available evidence suggests a non-linear association between ALP activity and CVD risk,
which is partly dependent on CRP. Taking account of conventional risk factors, additional
information on ALP does not improve CVD risk assessment.
Introduction
Alkaline phosphatase (ALP) is a hydrolase enzyme, which is widely expressed in human tis-
sues, but is highly concentrated in the liver, bone, and kidney [1]. Although its exact physiolog-
ical function is unclear, serum ALP activity has commonly been used in clinical practice as a
marker of hepatobiliary and bone disease [2]. Alkaline phosphatase is an inflammatory media-
tor like C-reactive protein (CRP) (a novel risk marker for cardiovascular disease [3]). Both
ALP and CRP have consistently been shown to be directly and significantly associated with
each other, with suggestions that they share common biological pathways [4–6]. Over the past
decade, serum ALP has sparked interest as an emerging marker for cardiovascular risk in the
general population, but uncertainty exists because important questions pertaining to its associ-
ation with CVD remain unresolved. A limited number of population-based prospective cohort
studies have generally suggested a positive association [2, 7–9], but such studies were often
poorly powered or unable to adjust for potentially relevant confounders. For these reasons, the
nature, magnitude, and independence of the association remain unclear. Furthermore, the
majority of these studies were conducted in selected populations such as in the elderly or par-
ticipants with coexisting morbidities [2, 7–9]. In our recently published literature-based meta-
analysis of studies assessing the associations of liver enzymes and CVD risk in participants
recruited from approximately general populations, the results suggested a modest positive lin-
ear association between ALP activity and CVD risk [10]. However, because only limited pub-
lished studies with few data points were available for pooling, the uncertainties existing for
ALP could not be adequately addressed.
With the emerging interest in the potential value of ALP activity in CVD risk prevention,
there is a need to provide robust evidence on the association of baseline ALP values with risk of
future CVD events in the general population using long-term observational data. Our primary
objective was to characterize and quantify the nature and magnitude of the prospective associa-
tion between ALP activity and risk of CVD using a large population-based sample of 6,974 par-
ticipants free from CVD at entry. In a recent report, Wannamethee and colleagues reported
considerable weakening of the association between ALP and CVD, following adjustment for
CRP [7]. Therefore, to put the interdependence between ALP and CRP levels into clinical per-
spective, we also aimed to determine whether the ALP-CVD relationship is confounded or
modified by CRP. Finally, we aimed to investigate for the first time, the extent to which ALP
measurements could improve the prediction of first-onset CVD outcomes in general popula-
tion settings when added to a conventional risk prediction model.
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Methods
Study participants
For this study, we used primary data from the Prevention of Renal and Vascular End-stage Dis-
ease (PREVEND) study, an observational, general population based cohort study in the Neth-
erlands, which began in 1997. Details of the study design and recruitment have been described
in detail elsewhere [11]. Briefly, this prospective study was designed to investigate the natural
course of urinary albumin excretion and its relation to renal and cardiovascular disease. The
actual PREVEND cohort (N = 8,592) was recruited from inhabitants (aged 28–75 years) of the
city of Groningen, the Netherlands. Baseline measurements were performed between 1997 and
1998. Baseline measurements were performed between 1997 and 1998. Participants with a his-
tory of prevalent CVD, liver disease, renal disease, or malignancy were excluded. The final
cohort for this analysis included 6,974 subjects with non-missing information on ALP values
and several CVD risk markers. The PREVEND study has been approved by the medical ethics
committee of the University Medical Center Groningen and was conducted in accordance with
the Declaration of Helsinki. Individual written informed consent was obtained from all partici-
pants, which was documented in a consent form approved by the medical ethics committee.
Risk factor assessment
Participants underwent two outpatient visits to assess baseline data on demographics, anthro-
pometric measurements, and cardiovascular risk factors. Venous blood was obtained after an
overnight fast and 15 minutes of rest. Plasma samples were prepared by centrifugation at 4°C.
Sera was stored at -20°C and heparinized plasma samples stored at -80°C until analysis. Plasma
glucose was measured by dry chemistry (Eastman Kodak, Rochester, New York). Total choles-
terol, high-density lipoprotein cholesterol (HDL-C), triglycerides, alanine aminotransferase
(ALT), gamma-glutamyltransferase (GGT), and high sensitivity C-reactive protein (hsCRP)
were measured as previously described [12, 13]. Serum creatinine was determined by Kodak
Ektachem dry chemistry (Eastman Kodak, Rochester, New York) and serum cystatin C level by
nephelometry (BN II N) (Dade Behring Diagnostic, Marburg, Germany). In a validation exper-
iment, we showed that serum creatinine levels as measured by dry chemistry are comparable to
levels measured by enzymatic method. Urinary albumin excretion (UAE) was calculated as the
mean of two 24-hour urine collections. Estimated glomerular filtration rate (eGFR), was calcu-
lated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) combined
creatinine-cystatin C equation [14]. Serum ALP activity was measured using a standardized
enzymatic method on a Roche Modular P analyzer (Roche, Mannheim, Germany) according
to the recommendations of the International Federation of Clinical Chemistry [15]. The refer-
ence ranges for ALP values employed by our laboratory was< 98 U/L for females and< 115
U/L for males. Hypertension was defined as systolic blood pressure (SBP) of140 mmHg, a
diastolic blood pressure (DBP) of90 mm Hg, or use of antihypertensive medication accord-
ing to self-report or to pharmacy data. Diabetes was defined as a fasting glucose level of 7.0
mmol/l, a nonfasting glucose level of11.1 mmol/l or use of antidiabetic medication according
to self-report or to pharmacy data [16].
Endpoint ascertainment
The primary outcome was first-onset CVD events (morbidity and mortality) with subsidiary
analyses of incident coronary heart disease (CHD) and stroke outcomes. Date and cause of
death were obtained by record linkage with the Dutch Central Bureau of Statistics, while infor-
mation on hospitalization for cardiovascular morbidity was received from PRISMANT, the
Alkaline Phosphatase and CVD Risk
PLOS ONE | DOI:10.1371/journal.pone.0132822 July 13, 2015 3 / 16
Dutch national registry of hospital discharge diagnoses. The validity of this database has been
shown to be good, with 84% of primary diagnoses and 87% of secondary diagnoses matching
the diagnoses recorded in patients’ charts [17, 18]. All data were coded according to the Inter-
national Classification of Diseases, Ninth Revision (ICD-9) and the classification of interven-
tions. Cardiovascular outcomes were defined as the combined incidence of acute myocardial
infarction (ICD-9 code 410), acute and subacute ischemic heart disease (ICD-9 code 411), cor-
onary artery bypass grafting (ICD-9 code 414) or percutaneous transluminal coronary angio-
plasty, subarachnoid hemorrhage (ICD-9 code 430), intracerebral hemorrhage (ICD-9 code
431), other intracranial hemorrhage (ICD-9 code 432), occlusion or stenosis of the precerebral
(ICD-9 code 433) or cerebral (ICD-9 code 434) arteries, and other vascular interventions such
as percutaneous transluminal angioplasty or bypass grafting of peripheral vessels (ICD-9 code
440) and aorta (ICD-9 code 441).
Statistical analyses
The principal analyses were pre-specified to exclude participants with a history of CVD at base-
line. The primary outcome was first-onset CVD, defined as fatal or nonfatal CHD event or
any stroke. Positively skewed variables (e.g., ALT, ALP, GGT, triglycerides, hsCRP, creatinine,
and UAE) were natural log-transformed to achieve approximately normal distributions. We
performed descriptive analyses summarizing baseline characteristics of participants. Cross-
sectional associations of ALP with risk markers for CVD were assessed using linear regression
models adjusted for age and sex. Time-to-event analyses were conducted using Cox propor-
tional hazards models [19] to examine the association of baseline ALP values with risk of CVD
after confirming assumptions of proportionality of hazards [20]. The shape of the association
of ALP values with CVD risk was assessed by plotting hazard ratios (HRs) calculated within
quintiles of baseline ALP values against the mean loge ALP value within each quintile using
floating absolute risks (FARs) [21]. As the association showed a non-linear shape, ALP was not
modelled continuously, but entered as fifths defined according to its baseline distribution.
Because of the relatively flat risk of CVD across quintiles 1–4, these categories were combined
and served as the reference comparison. Hazard ratios were adjusted for established CVD risk
factors [age, sex, smoking status, history of diabetes, SBP, total cholesterol, and HDL-C] and
further for body mass index (BMI), alcohol consumption, fasting glucose, triglycerides, eGFR,
UAE, and hsCRP. We performed subgroup analyses using interaction tests to assess statistical
evidence of any differences in HRs across categories of pre-specified individual characteristics
(such as age, sex, history of diabetes, smoking status, alcohol consumption, BMI, SBP, total
cholesterol, HDL-C, triglycerides, eGFR, UAE, and hsCRP). Subsidiary analyses included fur-
ther adjustment for other liver enzymes, GGT and ALT. To avoid potential bias due to reverse
causation, we carried out subsidiary analyses that excluded participants with a diagnosis of dia-
betes at baseline, CVD events ascertained in the first two years of follow-up, participants on
regular anti-hypertensive medication, and participants on regular lipid-lowering medication
(statins). Subsidiary analysis also involved excluding participants with increased albuminuria
(UAE 30 mg/24 hours), as it is a well-established cardiovascular risk marker [22]. Finally, we
conducted sensitivity analyses which employed the use of complex survey design analyses [23],
taking into account that the PREVEND cohort is oversampled for subjects with higher albu-
minuria levels, thereby enabling the results to be extrapolated to the broader (general)
population.
To assess whether adding information on ALP values to conventional cardiovascular risk
factors is associated with improvement in prediction of CVD risk, we calculated measures of
discrimination and reclassification [24, 25] for censored time-to-event data (Harrell’s C-index
Alkaline Phosphatase and CVD Risk
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[26]). Since recently developed risk prediction scores [27, 28] predict a composite CVD end-
point (combining outcomes of CHD and stroke) and because these outcomes share common
risk factors and treatments, the primary outcome for our risk prediction analysis was any first
CVD event. To investigate the change in C-index on addition of ALP, we added ALP to a
model based on risk factors included in the Framingham CVD Risk Score (i.e., age, sex, smok-
ing status, SBP, total cholesterol, and HDL-C) [29]. For participants with at least 10 years of
follow-up, reclassification was assessed using the net-reclassification-improvement (NRI) [24,
25], by comparing the cardiovascular risk from the model containing conventional risk factors
to the predicted risk from the model containing conventional risk factors plus ALP. Reclassifi-
cation analysis was based on predicted 10-year CVD risk categories of low (<5%), intermediate
(5 to<7.5%), and high (7.5%) risk [30]. Risk discrimination and reclassification analyses
based on the Reynolds Risk Score (RRS) [31, 32], which has been shown to be better calibrated
for major CVD events than the Framingham CVDmodel [33] were also performed in subsidi-
ary analyses. Risk prediction analysis was restricted to participants without a known history of
diabetes at baseline. All statistical analyses were conducted using Stata version 13 (Stata Corp,
College Station, Texas) and P values were 2-sided.
Results
Baseline characteristics and correlates of ALP
Overall, the mean age at baseline of the 6,974 participants eligible for the present study was 48
(SD 12) years and 52% were women. Median (interquartile range) ALP value was 62 (24) U/L.
Baseline descriptive characteristics of the participants are shown in Table 1. Loge ALP values
were modestly and positively correlated with age (r = 0.30), loge GGT (r = 0.26), and loge
hsCRP (r = 0.25). There were weak and positive correlations with physical measures (BMI,
waist circumference, and blood pressure), as well as several lipid, metabolic, and renal function
(cystatin C and UAE) markers. Inverse correlations were observed for HDL-C and loge creati-
nine. Baseline ALP values were higher by 8% in men compared with women, by 9% in people
with diabetes compared with non-diabetics, and lower by 7% in current alcohol drinkers com-
pared with non-current alcohol drinkers (Table 1). Clinical and laboratory data of participants
by ALP quintiles are shown in S1 Table.
ALP levels and risk of incident CVD
During 65,041 person years at risk (median follow-up of 10.5 years), 737 incident CVD events
(annual rate 11.2/1000 person-years at risk) were recorded. In analyses adjusted for age and
sex, a non-linear approximately “J-shaped” relationship was observed between ALP values and
CVD risk. The shape of the association was similar on adjusting for several established risk fac-
tors (smoking status, history of diabetes, SBP, total cholesterol, and HDL-C,) and further for
BMI, alcohol consumption, glucose, loge triglycerides, eGFR, loge UAE, and loge hsCRP (Fig
1). Further analyses compared the top quintile versus bottom quintiles 1–4 of the ALP distribu-
tion. The age- and sex-adjusted HR for CVD was 1.51 (95% CI: 1.29 to 1.76; P<0.001), which
changed to 1.34 (95% CI: 1.14 to 1.56; P<0.001) following further adjustment for conventional
CVD risk factors. The results remained materially unchanged after additional adjustment for
BMI, alcohol consumption, glucose, loge triglycerides, eGFR, and loge UAE 1.33 (95% CI: 1.13
to 1.55; P<0.001). However, further adjustment for loge hsCRP somewhat attenuated the asso-
ciation 1.24 (95% CI: 1.05 to 1.45; P = 0.009) (Table 2). HRs did not change importantly in
analyses that excluded CVD outcomes recorded in the first two years of follow-up, participants
with a history of diabetes at baseline, participants on regular anti-hypertensive medication, par-
ticipants on regular lipid-lowering medication, or participants with UAE 30 mg/24 hours
Alkaline Phosphatase and CVD Risk
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Table 1. Baseline participant characteristics and cross-sectional correlates of alkaline phosphatase.
Mean (SD)
or %
Pearson correlation
r (95% CI)†
Percentage difference (95% CI)
in ALP levels per 1 SD higher
or compared to reference
category of correlate‡
Loge ALP (U/L) 4.12 (0.29) - -
Questionnaire
Sex
Female 51.7 Ref
Male 48.3 8% (7, 10)***
Age at survey (years) 48 (12) 0.30 (0.28, 0.32)*** 9% (8, 10)***
History of diabetes
No 97.0 - Ref
Yes 3.0 - 9% (5, 13)***
Smoking status
Non-smokers 30.6 - Ref
Current smokers 69.4 - 0% (-1, 2)
Alcohol consumption
Non-consumers 24.4 - Ref
Current consumers 75.6 - -7% (-8, -6)***
History of hypertension
No 90.1 - Ref
Yes 9.9 - -1% (-3, 1)
Regular use of anti-hypertensive medication
No 89.1 - Ref
Yes 10.9 - 0% (-2, 2)
Regular use of diabetic medication
No 99.0 - Ref
Yes 1.0 - 0% (-6, 7)
Regular use of lipid-lowering medication
No 97.5 - Ref
Yes 2.5 - 3% (-1, 8)
Physical measurements
BMI (kg/m2) 26.0 (4.2) 0.15 (0.13, 0.17)*** 4% (4, 5)***
Waist circumference (cm) 87.8 (13.0) 0.17 (0.14, 0.19)*** 5% (5, 6)***
SBP (mmHg) 128.2 (19.9) 0.14 (0.12, 0.17)*** 5% (4, 5)***
DBP (mmHg) 73.7 (9.7) 0.11 (0.09, 0.13)*** 3% (3, 4)***
Lipid markers
Total cholesterol (mmol/l) 5.63 (1.12) 0.12 (0.10, 0.14)*** 4% (3, 4)***
HDL-C (mmol/l) 1.34 (0.40) -0.17 (-0.19, -0.15)*** -5% (-6, -4)***
Loge triglycerides (mmol/l) 0.18 (0.53) 0.17 (0.14, 0.19)*** 5% (4, 6)***
Apo AI (g/l) 1.39 (0.30) -0.11 (-0.14, -0.09)*** -4% (-4, -3)***
Apo B (g/l) 1.03 (0.31) 0.12 (0.09, 0.14)*** 3% (3, 4)***
Metabolic, inﬂammatory, and renal function markers
Loge hsCRP (mg/l) 0.23 (1.17) 0.25 (0.22, 0.27)*** 7% (6, 8)***
Fasting plasma glucose (mmol/l) 4.82 (1.11) 0.11 (0.08, 0.13)*** 3% (2, 4)***
Loge creatinine (μmol/1) 4.41 (0.17) -0.06 (-0.09, -0.04)*** -2% (-3, -1)***
Cystatin C (mg/l) 0.79 (0.19) 0.08 (0.06, 0.10)*** 2% (2, 3)***
eGFR (ml/min/1.73 m2) 100.9 (39.7) -0.01 (-0.03, 0.01)*** -0% (-1, 0)
Loge UAE (mg/24 hours) 2.47 (0.96) 0.04 (0.01, 0.06)*** 1% (0, 2)*
(Continued)
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(S2 Table). Also, the associations generally did not vary significantly by levels or categories of
several clinically relevant characteristics and other risk markers (P for interaction 0.10 for
each; Fig 2). In an age- and sex-adjusted analysis, the ALP-CVD association was somewhat
attenuated after single additional adjustment for loge hsCRP (S3 Table). There was no evidence
of statistically significant effect modification by hsCRP on the association in age- and sex-
adjusted analysis (P for interaction = 0.58). In separate analyses for CHD and stroke, the initial
positive association of ALP activity with CHD in analyses adjusted for several established risk
factors and potential confounders lost significance upon further adjustment for hsCRP. With
respect to the shape of the ALP-CHD relationship, there was a continuous association in analy-
sis adjusted for age and sex, potentially consistent with a curvilinear shape, which was altered
(almost flat) on further adjustment for other covariates (S1 Fig). Further work is required to
determine the shape that better describes the association. There was no significant evidence of
an association with stroke in all models (Table 2). All the results remained similar on further
adjustment for GGT and ALT (S4 Table). To put the strength of the associations of ALP levels
with CVD, CHD, and stroke risk into context, comparisons were made to the associations of
hsCRP with these same outcomes. As expected, there were significant associations of hsCRP
with all cardiovascular outcomes and were of comparable strength (Table 3). All results were
essentially similar when design-based Cox regression analyses were performed (data not
shown).
ALP and CVD risk prediction
A CVD risk prediction model containing established risk factors yielded a C-index of 0.7843
(95% CI: 0.7689 to 0.7996). After addition of information on ALP values, the C-index was
0.7846 (95% CI: 0.7692 to 0.8000), representing a marginal increase of 0.0003 (95% CI: -0.0015
to 0.0022; P = 0.72) (Table 4). There were no significant differences in cardiovascular risk dis-
crimination according to individual level clinically relevant characteristics (S2 Fig). In addition,
there was no significant improvement in the classification of participants into predicted
10-year CVD risk categories (NRI: 0.20%, -1.19 to 1.58%; P = 0.78). There was no significant
improvement in risk discrimination and reclassification when the model containing the RRS
Table 1. (Continued)
Mean (SD)
or %
Pearson correlation
r (95% CI)†
Percentage difference (95% CI)
in ALP levels per 1 SD higher
or compared to reference
category of correlate‡
Loge GGT (U/L) 3.21 (0.63) 0.26 (0.23, 0.28)*** 8% (7, 9)***
Loge ALT (U/L) 3.03 (0.48) 0.19 (0.17, 0.22)*** 6% (5, 7)***
ALT, alanine aminotransferase; Apo AI, apolipoprotein AI; Apo B, apolipoprotein; BMI, body mass index; hsCRP, high sensitivity C-reactive protein; DBP,
diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined
creatinine-cystatin C equation); ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; HDL-C, high-density lipoprotein cholesterol; Ref, reference;
SD, standard deviation; SBP, systolic blood pressure; UAE, urinary albumin excretion
†Pearson correlation coefﬁcients between loge ALP and the row variables;
‡Percentage change in ALP values per 1 SD increase in the row variable (or for categorical variables, the percentage difference in mean ALP values for
the category versus the reference) adjusted for age and sex; asterisks indicate the level of statistical signiﬁcance:
*, p<0.05;
**, p<0.01;
***, p<0.001
doi:10.1371/journal.pone.0132822.t001
Alkaline Phosphatase and CVD Risk
PLOS ONE | DOI:10.1371/journal.pone.0132822 July 13, 2015 7 / 16
Fig 1. Hazard ratios for incident cardiovascular disease by baseline values of loge alkaline phosphatase using floating absolute risks. A, adjusted
for age and sex; B, adjustment as in A plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein
cholesterol; C, adjustment as in B plus body mass index, alcohol consumption, glucose, loge triglycerides, estimated glomerular filtration rate (as calculated
using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), and loge urine albumin excretion;D, adjustment as
in C plus loge C-reactive protein; the size of the box is proportional to the inverse of the variance of hazard ratio.
doi:10.1371/journal.pone.0132822.g001
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components was used: C-index change of 0.0001 (95% CI: -0.0010 to 0.0011; P = 0.96) and NRI
of -0.35% (-1.60 to 0.89%; P = 0.58) (S5 Table).
Discussion
In this large-scale population-based study of individuals without a history of CVD at baseline,
there were generally modest positive associations of ALP values with several cardiovascular
risk markers. We observed a non-linear approximately “J-shaped” association between ALP
and CVD risk in analyses adjusted for a comprehensive panel of established and potential con-
founders. Our finding of a non-linear relationship between ALP and CVD risk is compatible
with some previous reports. In the 20th year follow-up examination and analyses of the British
Regional Heart Study (BRHS), the results were suggestive of a non-linear association between
ALP and stroke/CVD events in older men aged 60 to 79 years [7]. In their 16 years follow-up
of over 10,000 participants aged 40–69 in the Circulatory Risk in Communities Study
(CIRCS), Shimizu and colleagues demonstrated a “U-shaped” association between ALP values
and stroke risk in both men and women [34]. Our data also suggest that baseline circulating
ALP is positively associated with first-ever CVD outcomes, independent of several established
risk factors plus potential confounders including other liver enzymes (GGT and ALT); how-
ever, the association was somewhat attenuated on further adjustment for hsCRP. The results
remained generally consistent across several clinically relevant subgroups and at different lev-
els of risk factors including hsCRP. The associations were also similar in several sensitivity
analyses. A significant association with CHD was observed in analyses adjusted for several
established risk factors and potential confounders but was attenuated after further adjustment
for hsCRP, consistent with findings from the BRHS. There was however no significant evi-
dence of an association with stroke, which was also consistent with the BRHS [7], but in con-
trast to that observed in CIRCS [34]. The differences in findings may be attributed to
differences in statistical power. In CIRCS [34], there was almost double the number of stroke
cases compared to our study or that of BRHS, therefore there is a likelihood that the null
Table 2. Association of alkaline phosphatase with incident cardiovascular disease, coronary heart disease, and stroke.
Quintiles of ALP Events / Total Model 1 Model 2 Model 3 Model 4
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Cardiovascular disease
Q1 –Q4 486 / 5,601 ref ref ref ref
Q5 251 / 1,373 1.51 (1.29 to 1.76) < 0.001 1.34 (1.14 to 1.56) < 0.001 1.33 (1.13 to 1.55) < 0.001 1.24 (1.05 to 1.45) 0.009
Coronary heart disease
Q1 –Q4 262 / 5,601 ref ref ref ref
Q5 136 / 1,373 1.53 (1.24 to 1.89) < 0.001 1.29 (1.05 to 1.60) 0.017 1.30 (1.05 to 1.61) 0.016 1.22 (0.98 to 1.52) 0.075
Stroke
Q1 –Q4 108 / 5,601 ref ref ref ref
Q5 48 / 1,373 1.19 (0.84 to 1.68) 0.319 1.06 (0.75 to1.50) 0.748 1.03 (0.73 to 1.47) 0.862 0.92 (0.65 to 1.32) 0.654
ALP,alkaline phosphatase; Q, quintile
Model 1: Age and sex
Model 2: Model 1 plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol
Model 3: Model 2 plus body mass index, alcohol consumption, glucose, loge triglycerides, estimated glomerular ﬁltration rate (as calculated using the
Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), and loge urinary albumin excretion
Model 4: Model 3 plus loge C-reactive protein.
doi:10.1371/journal.pone.0132822.t002
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results could be due to the low stroke event rates. In addition, given the different aetiologies
for the endpoints of stroke and CVD in general [35], large-scale studies for the particular car-
diovascular outcome of stroke are still warranted. In addition, our analyses indicate that addi-
tion of information on ALP values to conventional cardiovascular risk factors does not
importantly improve CVD risk prediction.
Fig 2. Hazard ratios for cardiovascular disease comparing top quintile versus bottom quintiles 1–4 of baseline ALP values, by several participant
level characteristics. Hazard ratios were adjusted for age, sex, smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-
density lipoprotein cholesterol (HDL-C); CI, confidence interval (bars); CRP, C-reactive protein; CVD, cardiovascular disease; Estimated GFR, glomerular
filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HR, hazard ratio; UAE,
urinary albumin excretion; *, P-value for interaction; Cut-offs used for body mass index, total cholesterol, HDL-C, triglycerides, estimated GFR, and high
sensitivity CRP are median values.
doi:10.1371/journal.pone.0132822.g002
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Possible explanations for findings
Potential mechanisms for increased cardiovascular risk in people with elevated values of ALP
have been postulated. Alkaline phosphatase catalyses the hydrolysis of inorganic pyrophos-
phate, an inhibitor of vascular calcification [1], which leads to vascular hardening and pro-
motes the atherosclerotic process [36]. In advanced atherosclerotic lesions, there is calcification
with increased expression of ALP [37]. Mechanisms related to impaired vascular homeostasis
or subclinical liver dysfunction have also been implicated [2, 34]. There is also a possibility that
this could be due to underlying vitamin D or parathyroid hormone status. Low levels of vita-
min D are usually associated with elevated ALP levels. Interestingly, a recent elegant study by
Table 3. Associations of hsCRPwith incident CVD, CHD and Stroke.
Models CVD CHD Stroke
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
6,974 participants and 737 cases 6,974 participants and 398 cases 6,974 participants and 156 cases
Model 1 1.41 (1.30 to 1.52) < 0.001 1.43 (1.30 to 1.59) < 0.001 1.46 (1.23 to 1.73) < 0.001
Model 2 1.27 (1.17 to 1.38) < 0.001 1.25 (1.11 to 1.41) < 0.001 1.37 (1.14 to 1.64) 0.001
Model 3 1.26 (1.17 to 1.38) < 0.001 1.24 (1.09 to 1.40) 0.001 1.41 (1.17 to 1.70) < 0.001
Hazard ratios are reported per 1 standard deviation increase in loge hsCRP levels; 1 standard deviation higher loge hsCRP was approximately equivalent
to three-fold higher hsCRP levels.
CHD, coronary heart disease; CVD, cardiovascular disease; hsCRP, high sensitivity C-reactive protein
Model 1: Age and sex
Model 2: Model 1 plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol
Model 3: Model 2 plus body mass index, alcohol consumption, glucose, loge triglycerides, estimated glomerular ﬁltration rate (as calculated using the
Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), and loge urinary albumin excretion.
doi:10.1371/journal.pone.0132822.t003
Table 4. Risk discrimination and reclassification upon addition of ALP to the Framingham CVD risk
predictionmodel containing conventional risk factors.
Discrimination
C-index (95% CI): conventional risk factors 0.7843 (0.7689 to 0.7996)
C-index (95% CI): conventional risk factors plus ALP 0.7846 (0.7692 to 0.8000)
C-index change (95% CI) 0.0003 (-0.0015 to 0.0022)
P-value 0.72
Reclassiﬁcation
Participants who did not develop CVD at 10 years
Appropriately reclassiﬁed 112 (2.39%)
Inappropriately reclassiﬁed 110 (2.35%)
No change 4,465 (95.26%)
Participants who developed CVD at 10 years
Appropriately reclassiﬁed 9 (1.37%)
Inappropriately reclassiﬁed 8 (1.22%)
No change 639 (97.41%)
Net reclassiﬁcation index (95% CI) 0.20% (-1.19% to 1.58%)
P-value 0.78
The model with conventional risk factors included age, sex, smoking status, systolic blood pressure, total
cholesterol, and high-density lipoprotein cholesterol; CVD, cardiovascular disease; ALP, alkaline
phosphatase.
doi:10.1371/journal.pone.0132822.t004
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Durup and colleagues has demonstrated a reverse J-shaped association between vitamin D (as
measured by 25-hydroxyvitamin D) and CVD mortality [38]. We did not have data on vitamin
D levels and therefore could not investigate this possibility. Additionally, ALP values are
known to be elevated in obese patients and may play a role in adipogenesis [5, 39]. There are
also suggestions that inflammation may be the common link between ALP and CVD develop-
ment [2, 9]. Alkaline phosphatase is an acute phase reactant [40], which is associated with CRP
[4, 5, 41], the most commonly used marker of low-grade chronic inflammation. Elevated values
of ALP may therefore reflect inflammation of hepatic origin, given that CRP is secreted by the
liver [7]. Our observed ALP-CVD association was materially attenuated after adjusting for
hsCRP in both analyses initially only adjusted for age and sex and further for several conven-
tional risk factors, which supports the hypothesis that inflammatory processes may play a role
in the aetiology between ALP and CVD risk. In line with the recent report by Wannamethee
and colleagues, the association between ALP and CVD was considerably weakened after adjust-
ment for hsCRP [7]. If hsCRP mediates the association between ALP activity and risk of CVD,
then correction for hsCRP could be an overadjustment. Evidence supportive of potential causal
pathways may need to be confirmed in appropriate interventional studies or Mendelian ran-
domization studies [42].
Implications of findings
Our findings are relevant and may have clinical implications. They underscore a potentially
deleterious role of increasing ALP activity on future risk of CVD/CHD in general populations.
Elevations in ALP activity suggest decreased inhibition of vascular calcification, which is asso-
ciated with myocardial infarction and coronary death [43] and is a significant risk factor in the
pathogenesis of CVD. Results from a study in rat models have found evidence to support a sub-
stantial vascular calcification reduction effect of three novel inhibitors (5361418, 5923412, and
5804079) of the physiological pyrophosphate activity of ALP [44]. Therapies such as activated
vitamin D products and calcimimetics have also been shown to lower levels of circulating ALP
[45, 46]. Given that mitigation of vascular calcification is an emerging target in the treatment
of atherosclerosis [9], further studies on ALP inhibitors and interventions that lower elevated
activity of ALP are warranted. In the absence of such studies, individuals with increased ALP
values may need further clinical evaluation and close monitoring.
Strengths and limitations
The notable strengths include a large sample that was representative of the general population
and had a long follow-up duration. There was information on a comprehensive panel of life-
style and biological markers to allow adequate adjustment for potential confounding, enabling
reliable assessments of the ALP-CVD association. In order to limit any possibilities of reverse-
causation bias, this current study was designed to involve individuals free of prior vascular or
malignant disorders at baseline. Our results remained robust in several sensitivity analyses.
The reliability of the data was also confirmed by our ability to replicate the independent associ-
ation of hsCRP with cardiovascular outcomes [3]. In addition to the several strengths enumer-
ated, our study did have some limitations. It was not possible to correct the estimates for
within-individual variation in values of ALP over time which can cause underestimation of
associations, because repeat ALP measurements were not available. There is evidence to suggest
that ALP values in individuals can fluctuate over time [47], hence, the associations demon-
strated may be even stronger. Owing to the observational nature of data available, potential
residual confounding due to errors in risk marker measurements and other unmeasured con-
founders (such as serum calcium, parathyroid hormone, and vitamin D) cannot be entirely
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ruled out. Assays for total circulating ALP were used, therefore it was not possible to evaluate
which ALP isoenzyme [48] was associated with CVD risk.
Conclusions
In conclusion, our data suggest a non-linear positive association between circulating ALP activ-
ity and CVD risk, which is partly dependent on CRP. Given knowledge of conventional risk
factors, additional information on ALP does not improve CVD risk assessment.
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